Altre lingue Acumen Pharmaceuticals, Inc.

Azioni

ABOS

US00509G2093

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 02/07/2024			Variaz. 5gg	Var. 1 gen.
2,27 ^USD	-4,82%		+6,07%	-40,89%

15/05	Transcript : Acumen Pharmaceuticals, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 08:55 AM
14/05	Transcript : Acumen Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 14, 2024

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

Acumen Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05
Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights	14/05
Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference	13/05
Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference	08/05
Acumen Pharmaceuticals Doses 1st Patient in Alzheimer's Disease Drug Study	08/05
Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease	08/05
Acumen Pharmaceuticals, Inc. Announces First Patient Dosed in Altitude-Ad, A Phase 2 Clinical Trial of Sabirnetug in Early Alzheimer?S Disease	08/05
Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024	07/05
AAN 2024 Poster - INTERCEPT-AD, a Phase 1 Study of Sabirnetug (ACU193): Safety, Target Engagement, and Biomarker Changes	02/05
Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug at American Academy of Neurology 2024 Annual Meeting	17/04
Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting	16/04
Acumen Pharmaceuticals Signs Deal With Lonza to Manufacture Alzheimer's Treatment Drug	04/04
Lonza Enters Manufacturing Agreement for Acumen’s Alzheimer’s Disease Drug Candidate	04/04
Lonza produziert Arzneimittelkandidaten von Acumen Pharmaceuticals	04/04
Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s Disease	04/04
Acumen Pharmaceuticals, Inc. Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer?S Disease	04/04
Acumen Pharmaceuticals Files $200 Million Mixed Shelf	27/03
Acumen Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26/03
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights	26/03
Acumen Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26/03

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Acumen Pharmaceuticals, Inc.

Azioni

ABOS

US00509G2093

Altre lingue

Filtri